Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $92.1 million.

  • Abivax's Total Current Liabilities changed N/A to $92.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.1 million, marking a year-over-year change of. This contributed to the annual value of $100.4 million for FY2024, which is 238.57% up from last year.
  • Per Abivax's latest filing, its Total Current Liabilities stood at $92.1 million for Q3 2025.
  • Abivax's 5-year Total Current Liabilities high stood at $127.2 million for Q2 2025, and its period low was $36.9 million during Q4 2021.
  • Over the past 5 years, Abivax's median Total Current Liabilities value was $94.8 million (recorded in 2023), while the average stood at $88.0 million.
  • In the last 5 years, Abivax's Total Current Liabilities skyrocketed by 8584.99% in 2023 and then soared by 293.55% in 2024.
  • Over the past 5 years, Abivax's Total Current Liabilities (Quarter) stood at $36.9 million in 2021, then surged by 42.25% to $52.5 million in 2022, then surged by 85.85% to $97.6 million in 2023, then grew by 2.94% to $100.4 million in 2024, then decreased by 8.33% to $92.1 million in 2025.
  • Its last three reported values are $92.1 million in Q3 2025, $127.2 million for Q2 2025, and $111.2 million during Q1 2025.